Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Unknown 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4Endocrine 4

Conditions

Differentiated Thyroid Cancer 4Thyroid Neoplasms 3Thyroid Cancer, Papillary 1Adenocarcinoma, Follicular 1

Interventions

Thyrotropin Alfa 4donafenib 2Injections 2vandetanib 1anlotinib 1Iodine-131 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Differentiated Thyroid Cancer × Thyrotropin Alfa × Clear all
NCT04971473 2024-03-28

Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Completed
201 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04137185 2024-03-06

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Completed
64 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04447183 2023-10-23

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Unknown
120 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04964284 2023-10-23

Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Unknown
328 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡